CN101168555B - 一种药物及其衍生物的制备 - Google Patents
一种药物及其衍生物的制备 Download PDFInfo
- Publication number
- CN101168555B CN101168555B CN2006100162815A CN200610016281A CN101168555B CN 101168555 B CN101168555 B CN 101168555B CN 2006100162815 A CN2006100162815 A CN 2006100162815A CN 200610016281 A CN200610016281 A CN 200610016281A CN 101168555 B CN101168555 B CN 101168555B
- Authority
- CN
- China
- Prior art keywords
- fluocortolone
- reaction
- compound
- ketone
- ocor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- -1 steroid compound Chemical class 0.000 claims abstract description 19
- 238000003747 Grignard reaction Methods 0.000 claims abstract description 18
- 239000007858 starting material Substances 0.000 claims abstract description 10
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical class C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims description 72
- 229960003973 fluocortolone Drugs 0.000 claims description 55
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 15
- 235000019439 ethyl acetate Nutrition 0.000 claims description 12
- 150000002576 ketones Chemical class 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229940070710 valerate Drugs 0.000 claims description 9
- 239000007818 Grignard reagent Substances 0.000 claims description 8
- 150000004795 grignard reagents Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 238000006386 neutralization reaction Methods 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- 150000005826 halohydrocarbons Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 13
- 230000032050 esterification Effects 0.000 abstract description 9
- 238000005886 esterification reaction Methods 0.000 abstract description 9
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 6
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 238000007599 discharging Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 5
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 5
- 239000003513 alkali Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- TWJVNKMWXNTSAP-UHFFFAOYSA-N azanium;hydroxide;hydrochloride Chemical compound [NH4+].O.[Cl-] TWJVNKMWXNTSAP-UHFFFAOYSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000005649 metathesis reaction Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 0 C[C@@]1(C[C@@]2O)C(C(C*)=O)=CCC1C(C[C@@](C(C1(C)C=C3)=CC3=O)F)[C@]21F Chemical compound C[C@@]1(C[C@@]2O)C(C(C*)=O)=CCC1C(C[C@@](C(C1(C)C=C3)=CC3=O)F)[C@]21F 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- FIHJYAXZMHPSEY-OCZZRDIOSA-N C[C@H](CC(C(CC(C([C@]1(C)C=C2)=CC2=O)=[F-])[C@@]11F)[C@]2(C)C[C@@H]1O)C2C(C)=O Chemical compound C[C@H](CC(C(CC(C([C@]1(C)C=C2)=CC2=O)=[F-])[C@@]11F)[C@]2(C)C[C@@H]1O)C2C(C)=O FIHJYAXZMHPSEY-OCZZRDIOSA-N 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical class C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100162815A CN101168555B (zh) | 2006-10-27 | 2006-10-27 | 一种药物及其衍生物的制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100162815A CN101168555B (zh) | 2006-10-27 | 2006-10-27 | 一种药物及其衍生物的制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101168555A CN101168555A (zh) | 2008-04-30 |
CN101168555B true CN101168555B (zh) | 2011-05-04 |
Family
ID=39389345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100162815A Expired - Fee Related CN101168555B (zh) | 2006-10-27 | 2006-10-27 | 一种药物及其衍生物的制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101168555B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928318A (zh) * | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | 一种含氟甾体激素的制备 |
CN103130860B (zh) * | 2011-11-30 | 2016-05-18 | 天津金耀集团有限公司 | 一种双氟可龙戊酸酯新晶型及其制备的局部外用制剂 |
CN107793460A (zh) * | 2016-08-30 | 2018-03-13 | 天津太平洋制药有限公司 | 一种氟可龙的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB869511A (en) * | 1958-05-26 | 1961-05-31 | Upjohn Co | Improvements in or relating to steroids and the manufacture thereof |
CN1052489C (zh) * | 1992-06-11 | 2000-05-17 | 鲁索-艾克勒夫公司 | 制备16α-甲基甾族化合物的方法 |
-
2006
- 2006-10-27 CN CN2006100162815A patent/CN101168555B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB869511A (en) * | 1958-05-26 | 1961-05-31 | Upjohn Co | Improvements in or relating to steroids and the manufacture thereof |
CN1052489C (zh) * | 1992-06-11 | 2000-05-17 | 鲁索-艾克勒夫公司 | 制备16α-甲基甾族化合物的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101168555A (zh) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111560045A (zh) | 一种以ba为原料合成石胆酸的方法 | |
DE2453648B2 (de) | Verfahren zur Herstellung von 1 a -Hydroxycholesterinen sowie 1 alpha , 2 a -Epoxy-6 ß sulfonyloxyderivate des S a -Cholestan-3-ons als Zwischenprodukte | |
CN104876995A (zh) | 鹅去氧胆酸衍生物的制备方法 | |
CN113651866B (zh) | 一种以21-羟基-20-甲基孕甾-4-烯-3-酮为原料合成胆固醇的新方法 | |
CN105001293B (zh) | 雌酚酮的制备方法 | |
CN101168555B (zh) | 一种药物及其衍生物的制备 | |
CN114380879A (zh) | 一种微通道反应器制备黄体酮中间体及黄体酮的方法 | |
CN106928222B (zh) | 一种3-烷基中氮茚衍生物的制备方法 | |
CN103980336A (zh) | 一种新的氟维司群的合成方法 | |
CN102584521A (zh) | 一种氯代炔烃的合成方法 | |
CN102040636B (zh) | α-D-葡萄糖五乙酸酯合成β-熊果苷 | |
CN110862323A (zh) | 一种二氨基二苯乙烷化合物的合成方法 | |
CN101302207B (zh) | 3-ο-烷基-5,6-ο-(1-甲基乙叉基)-l-抗坏血酸的制造方法以及5,6-ο-(1-甲基乙叉基)-l-抗坏血酸的制造方法 | |
CN101973932A (zh) | 一种比沙可啶的制备方法 | |
CN104098502B (zh) | 一种(S)-α-羟基-γ-N-邻苯二甲酰氨基丁酸的合成方法 | |
CN104628653A (zh) | 合成瑞舒伐他汀钙关键中间体的方法 | |
Yang et al. | Synthesis of 2-C-Fluoromethyl-Myo-Inositol | |
CN109096348B (zh) | 一种磺达肝癸钠单糖中间体的制备方法 | |
CN107200729B (zh) | 一种4-(2-甲氧基苯基)-5-(2-吡啶基)-3-氨基异恶唑的制备方法 | |
CN103665054B (zh) | 异乳糖的制备方法 | |
CN113149973A (zh) | 一种恩格列净的合成方法 | |
CN111518148A (zh) | 一种天麻素中间体的合成方法 | |
CN104109185A (zh) | 一种醋酸阿比特龙的制备方法 | |
CN114507245B (zh) | 一种伊多塞班及其中间体的制备方法 | |
CN114437169B (zh) | 一种屈螺酮关键中间体溴代物的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300161 Tianjin City Hedong District Forest Road No. 91 Patentee after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300161 Tianjin City Hedong District Forest Road No. 91 Patentee before: TIANJIN PHARMACEUTICALS Group Corp. |
|
CP01 | Change in the name or title of a patent holder | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 300457 Tianjin Binhai New Area Tianjin Development Zone West District Xinye Jiujie north, Xinhuan West Road East Patentee after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300161 Tianjin City Hedong District Forest Road No. 91 Patentee before: Tianjin Pharmaceutical Research Institute Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 300457 North Xinye 9th Street and East Xinhuan West Road, West District, Binhai New Area Development Zone, Tianjin Patentee after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300457 Tianjin Binhai New Area Tianjin Development Zone West District Xinye Jiujie north, Xinhuan West Road East Patentee before: Tianjin Pharmaceutical Research Institute Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20211027 |